Navigation Links
China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results

    CHANGCHUN, China and LOS ANGELES, April 23 /PRNewswire-Asia-FirstCall/ --

    - Fourth Quarter 2008 Revenue Increased 28.6% to $14.1 Million, with Net
      Income was $0.9 Million and Diluted EPS of $.03

    - 2008 Revenues Increased 23.5% to $59.1 Million vs. 2007

    - 2008 Gross Profit Margin Improved 340 Basis Points to 20.1%

    - 2008 Net Income Increased 13.7% to $4.1 Million with Diluted EPS of

    - 2008 Cash Flow from Operations was $5.9 million

China Yongxin Pharmaceuticals, Inc. ("China Yongxin Pharmaceuticals" or "the Company") (OTC Bulletin Board: CYXN), a leading manufacturer, distributor and retailer of pharmaceuticals in Northeastern China, today announced Annual 2008 financial results ended December 31, 2008.

Fourth Quarter Ending December 31, 2008 Financial Results

Yongxin announced record revenue for its fourth quarter of $14.1 million, representing a 28.6% increase from $11 million recorded in the fourth quarter of fiscal 2007. Growth was driven by increased sales from both its wholesale distribution and retail business segment.

Gross profit in the fourth quarter 2008 was $3.5 million, a 122.8% increase from $1.6 million in the fourth quarter of 2007. Gross margins were 24.6% in the fourth quarter of 2008, compared to 14.2% in the fourth quarter of 2007.

Operating expenses were approximately $2 million, representing a 112.6% increase from approximately $1 million in the fourth quarter of 2007, and were directly related to increased marketing and selling expenses. Income from operations was $1.4 million, an increase of 138.8% from $0.6 million in the same period of 2007. Operating margins were 10.1% compared to 5.4%.

Net income for the quarter was $0.9 million, down from net income of $1.3 million in the same period a year ago. Income taxes were approximately $346,053 and 0 representing an effective tax rate of 25% and 0% for the fiscal fourth quarter of 2008 and 2007 respectively.

Diluted earnings per share were $0.03 for the fourth quarter of 2008, compared to diluted earnings per share of $0.06 in the fourth quarter of 2007, utilizing 31.2 million shares and 21 million shares respectively. The variance in net income and earnings per share was related to recapitalization on reverse merger.

Fiscal Year Ending December 31, 2008 Financial Results

For the fiscal year ended December 31, 2008, Yongxin announced record revenue of $59.1 million, a 23.5% increase versus $47.9 million reported for 2007. Revenues from the pharmaceutical wholesale business segment increased approximately 25.8% from $38.3 million in 2007 to $48.3 million in 2008, while revenues for retail chain drugstores increased approximately 15.1% to $10.9 million in 2008. Increased demand for its portfolio of pharmaceutical products by a broader customer base and higher sales volume overall, and the addition of 14 new drugstores were the principal drivers of growth year over year. Yongxin Drugstore, Jingyongxin Drugstore and Caoantang Drugstore, three new subsidiaries added in mid-2007, grew rapidly in 2008, which brought in additional revenues and contributed to overall revenue growth.

Cost of goods sold was approximately $47.2 million, yielding a gross profit of $11.9 million and gross margins of 20.1%, compared to $8.0 million in gross profit and a gross margin of 16.7% for fiscal year of 2007. Thus, gross profits grew by 48.8% and gross profit margin improved 340 basis points on a year-over-year basis. The improved margins were primarily attributable to the company's ability to receive larger volume discounts for purchases to service a greater revenue base, in addition to a product mix which included higher profit margin cosmetics and health and organic products. During 2008, the Company added 486 new products for distribution, 343 of these were granted exclusive distribution rights in Jilin province.

Operating expenses, which include selling, general and administration expenses for fiscal year 2008, were $6.1 million, up 57.7% compared to the same period in 2007. Selling expenses for the period increased to approximately $3.6 million from $2.6 million in 2007, which is a result of increased marketing efforts. General and administrative expenses increased to $2.6 million in 2008 from $1.3 million in 2007. The increase was mainly due to the increased expenses related to the public market.

Operating income totaled approximately $5.8 million, a 40.5% increase from the $4.1 million reported for fiscal year 2007. Operating margins were 9.8% and 8.6% for the fiscal year 2008 and 2007, respectively.

For fiscal 2008, net income was approximately $4.1 million, an increase of 13.7% from $3.6 million recorded for fiscal 2007. The provision for income taxes was $1.0 million and $17,888, yielding an effective tax rate of 16% and 0.4% for 2008 and 2007 respectively and thus impacted the year-over-year net income comparison.

Fully diluted earnings per share for 2008 and 2007 were $0.13 and $0.16 respectively, based on 31.2 million and 22.4 million shares for 2008 and 2007, respectively. This increase in outstanding shares was related to recapitalization on reverse merger. The share count does not include 5 million shares of preferred stock owned by the management, which is convertible to up to 30 million shares of common stock.

"We are very pleased with our strong financial performance in 2008 despite the global recession as growth emanated from increased sales through our pharmaceutical wholesale business to a larger base of customers complemented by higher margin products in addition to contributions from our retail chain drugstores where we launched 14 new locations during 2008," commented Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin. "Our multi-pronged growth strategy is proving to be successful as evidenced by this growth in revenue and net income for 2008."

"Revenues generated from prescription drugs represented approximately 25% of total drugstore sales with gross margins of approximately 23.5%. We successfully launched our Electronic Diagnosis System in the 42 chain drugstores located in Changchun, Jilin Province and where we have experienced an approximate 25% increase in prescription drug sales in these stores. We plan to introduce this service to the balance of our retail drugstores, which we expect to drive market share gains and incremental revenue growth during 2009 and beyond. The Chinese government recently released its new plan to spend $124 billion on healthcare reform during the next three years, which will provide accessible and affordable healthcare to the country's 1.3 billion citizens. We believe this healthcare plan will significantly increase the overall market size and our strategic location and strong reputation in Northeastern China will enable us to capitalize on this opportunity, while creating further value for our shareholders," concluded Mr. Liu.

Balance Sheet and Cash Flow

The Company had a current ratio of 1.8 to 1 and $0.6 million in cash and cash equivalents on December 31, 2008. Stockholders' equity was $13.6 million, with working capital of $10.2 million and total assets of $31.5 million and total liabilities of $18 million. Days Sales Outstanding for fiscal 2008 were 37 days, a considerable decrease compared to the 50 days reported during 2007. For the fiscal year of 2008, the Company generated $5.9 million in cash from operations versus net cash used in operations of $1.8 million for the same period in 2007. The increase in cash flow was primarily attributable to an increase in net income and decrease in accounts receivable, advances to suppliers and inventory, while partially offset by a decrease in accounts payable.

About China Yongxin Pharmaceuticals, Inc.

China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), a wholesale drug distributor. Its products include Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment. It began retail operations in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing pharmaceutical companies in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit .

Forward Looking Statements

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.

    For more information, please contact:

    For the Company:
     Mr. Sam Liu, COO
     China Yongxin Pharmaceuticals, Inc.
     Tel:   +1-626-581-9098

     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155

                        (FORMERLY NUTRADYNE GROUP, INC.)
                           CONSOLIDATED BALANCE SHEETS
                        AS OF DECEMBER 31, 2008 AND 2007

                                           2008                     2007
    Current Assets:
      Cash and cash equivalents          $609,422               $1,180,029
      Accounts receivable, net          6,030,874                6,586,105
      Notes receivable                  1,334,078                       --
      Other receivable, net               356,573                  207,337
      Advances to suppliers             6,186,269                5,729,235
      Prepaid expenses                    345,686                  319,074
    Inventory, net                      7,864,677                6,257,450
    Total Current Assets               22,727,579               20,279,230

    Property and Equipment, net         2,680,207                2,038,629

    Construction In Progress            6,066,249                       --

    Intangible Assets, net                 73,687                   81,152
    Total Assets                      $31,547,722              $22,399,011


    Current Liabilities:
      Accounts payable                 $3,255,148               $5,030,340
      Accrued expenses &
       other payable                    2,412,067                1,435,235
      Advances from customers           2,580,894                  799,910
      Tax payable                       1,240,411                  282,899
      Loan to related parties             184,662                1,722,557
      Short-term loan payable           1,967,185                  389,977
      Deferred income                     273,753                  239,937
      Shares to be issued                  35,000                   35,000
    Net liabilities of
     discontinued operations              628,837                  628,777
    Total Current Liabilities          12,577,956               10,564,632

    Long term loan                      1,320,390                  959,616
    Minority Interests                  4,098,940                2,640,128

    Commitments and Contingency                --                       --

    Stockholders' Equity:
      Preferred stock, $0.001 par
       value; 5,000,000 shares
       authorized; 5,000,000 shares
       issued and outstanding               5,000                    5,000
      Common stock; $0.001 par value;
       75,000,000 shares authorized;
       31,400,540 and 31,041,845
       shares issued and outstanding
       as of December 31, 2008
       and December 31, 2007               31,401                   31,042
        Additional paid in capital        615,906                       --
      Deferred consulting expense -
       issuance of warrants               (72,815)                      --
        Prepaid consulting -
         issuance of shares               (68,750)                      --
        Receivable from a
         related party                    (50,000)                      --
        Statutory reserve               1,841,241                1,341,600
        Other comprehensive income      1,684,649                  859,688
    Retained earnings                   9,563,803                5,997,305
    Total Stockholders' Equity         13,550,435                8,234,635
    Total Liabilities and
     Stockholders' Equity             $31,547,722              $22,399,011

                        (FORMERLY NUTRADYNE GROUP, INC.)
                 FOR THE YEARS ENDED DECEMBER 31, 2008 AND 2007

                                                  2008              2007
    Net Revenue                              $59,123,256       $47,892,833
    Cost of Revenue                           47,227,334        39,898,004
    Gross Profit                              11,895,922         7,994,829

    Operating Expenses
      Selling expenses                         3,553,923         2,561,721
      General and administrative expenses      2,556,133         1,314,229
    Total operating expenses                   6,110,056         3,875,950

    Income From Operations                     5,785,866         4,118,879

    Other Income (Expense)
      Interest income                              2,470             3,690
      Interest expense                            (9,148)         (194,644)
      Other income                               690,517           678,888
      Other expense                             (154,441)         (101,114)
    Total other income                           529,397           386,820

    Operating Income Before Income Tax And
    Minority Interest                          6,315,263         4,505,699

    Provision For Income Tax                  (1,009,643)          (17,888)

    Net Income Before Minority Interest        5,305,620         4,487,811

    Minority Interest                         (1,239,481)         (910,433)

    Net Income                                 4,066,139         3,577,378

    Other Comprehensive Item:
      Foreign Currency Translation Gain          824,961           590,885
    Net Comprehensive Income                   4,891,100         4,168,263

    Earning per share
      Basic                                        $0.13             $0.16
      Diluted                                      $0.13             $0.16

    Weighted average number of
     shares outstanding
      Basic                                   31,186,366        22,238,036
      Diluted                                 31,186,366        22,372,676

                         (FORMERLY NUTRADYNE GROUP, INC.)
                 FOR THE YEARS ENDED DECEMBER 31, 2008 AND 2007

                                                  2008              2007
    Net Income                                $4,066,139        $3,577,378

    Adjustments to reconcile net income to
     net cash used in / (provided by)
     operating activities:
    Depreciation and amortization                311,992           203,909
    Stock issued for consulting services         424,700                --
    Minority interest                          1,239,481           910,433

    (Increase) / decrease in current assets:
    Accounts receivable                          999,096        (3,577,120)
    Advances to suppliers                        (53,949)       (3,403,984)
    Other receivable                            (132,334)           59,064
    Notes receivable                          (1,310,799)               --
    Prepaid expenses                              (4,143)          (94,404)
    Inventory                                 (1,147,645)       (2,510,863)

    Increase / (decrease) in current
    Accounts payable                          (2,164,346)        1,400,423
    Accrued expense and other payable            903,925           625,276
    Deferred income                               16,679           230,968
    Advances from customers                    1,821,591           748,000
    Tax payable                                  924,573                --
    Net cash provided by/ (used in)
     operating activities                      5,894,960        (1,830,920)

    Cash acquired on reverse acquisition              --             5,334
    Contribution from minority shareholders       11,532                --
    Additions to construction in progress     (5,960,396)               --
    Purchase of property, equipment and
     intangible assets                          (789,036)       (1,029,925)
    Net cash used in investing activities     (6,737,900)       (1,024,591)

    Receipts of loan from non-related
     parties                                   1,818,271         1,187,673
    Receipts of Loan from banks                       --         1,516,067
    Payments of loan from non-related
     parties                                  (1,617,118)               --
    Net cash provided by financing
     activities                                  201,153         2,703,740

     EQUIVALENTS                                (641,786)         (151,771)

     CASH AND CASH EQUIVALENTS                    71,179            83,396

     BALANCE                                   1,180,029         1,248,404

     BALANCE                                    $609,422        $1,180,029

    Interest paid                               $167,156          $161,888
    Income tax paid                              $15,927            $8,563

    Issuance of shares and receivable from
     a related party                             $50,000               $--

SOURCE China Yongxin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Breaks Ground on Largest Comprehensive Stem Cell Storage and Processing Facility
2. China-Biotics, Inc. Supplies Probiotics as Additive for Poultry Feed
3. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
4. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
5. China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results
6. China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Results
7. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
8. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
9. China Agri-Business Announces 2008 Operating Results
10. China Biologic Products Announces Strong 2008 Results
11. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
Post Your Comments:
(Date:10/11/2017)... , ... October 11, 2017 , ... Personal eye wash is a basic first aid ... at a time. So which eye do you rinse first if a dangerous substance enters ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its dirt ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):